Over the past 12–18 months, most law firms have approved a surprising number of GenAI-related initiatives — tools, pilots, governance frameworks, training programs, and vendor evaluations.
Viewed individually, each decision made sense. Taken together, they reveal something more interesting: how the firm is actually sequencing its AI strategy.
Look at where time, attention, and budget have gone during that period. The pattern usually reveals which priorities are leading your AI investments — even if no explicit sequencing decision was ever made.
The challenge is learning to read those patterns.
Actions speak louder than words
Every firm has limited capacity — leadership attention, implementation bandwidth, and partner patience — and budget. Where those constraints get directed reveals priority.
Not what is stated in AI policies or presented in innovation decks — but what gets funded, protected, and resourced as initiatives move forward.
Across firms, three signals tend to reveal how GenAI strategy is being sequenced in practice.
What gets approved quickly
The initiatives that move forward most easily often reveal the firm’s implicit priority.
If governance frameworks and risk validation get resourced before capability building, Trust is leading the sequence.
If tool consolidation and utilization metrics get funded before broader expansion, Capital Discipline is leading.
If premium tools and client-facing AI capabilities receive early investment before deep adoption is proven, Competitive Positioning is leading.
Few firms consciously choose this order. But the pattern tends to emerge through repeated decisions.
What continues to receive attention
Initiatives rarely get cut outright in partnerships. More often, attention simply shifts.
The initiatives that continue receiving leadership attention — even as other priorities compete for time — are usually the ones the firm considers strategic.
A firm that emphasizes disciplined internal investment but continues to expand tool access faster than utilization can, reveals something important about its sequencing.
These signals are not contradictions. They are patterns worth reading carefully.
Who shapes the conditions of approval?
In partnerships, decisions rarely hinge on a single “yes” or “no.” Instead, initiatives move forward only after certain concerns have been satisfied.
If governance and risk questions must be resolved first, Trust is shaping the sequence.
If utilization expectations and investment scrutiny dominate early discussions, Capital Discipline is shaping the sequence.
If practice leaders and client-facing considerations accelerate adoption decisions, Competitive Positioning is shaping the sequence.
The concerns that must be satisfied before something moves forward often reveal more about strategy than any policy document.
The Gap Between Language and Capital
Most firms speak about all three strategies simultaneously — and mean it. Leadership genuinely wants strong governance, disciplined investment, and competitive positioning.
These tensions persist not because anyone is wrong, but because capital allocation has quietly favored one while leadership language has honored all three.
A firm may present an innovation-forward narrative externally while allocating primarily toward risk containment internally. A firm may emphasize ROI discipline in partner meetings while expanding tool access faster than utilization can follow. These aren’t contradictions — they’re signals worth reading clearly.
When sequencing is implicit, the three strategic factions each believe their priority is leading. That’s where the friction lives. When sequencing is explicit, trade-offs feel deliberate rather than political.
A Diagnostic Worth Running
Before any strategy conversation, consider asking three questions about the past 12–18 months of GenAI-related spending:
- Where has investment increased most — governance and risk infrastructure, utilization measurement, or tools and external positioning?
- Which initiatives would be hardest to cut if you needed to find 10–15% in reductions tomorrow?
- When a client asks how your AI investments benefit them, what is the first justification that surfaces — risk control, efficiency, or differentiation?
The answers rarely produce a clean result. Most firms will see a mix. But the pattern usually points somewhere — and that pattern is more useful than starting a strategy conversation from scratch, because it reflects real choices already made under real constraints.
Why This Is the Right Starting Point
A practical starting point is simple, but rarely easy: build a one-page inventory of every GenAI-related initiative over the past 24 months — tools, pilots, governance work, training, and infrastructure upgrades — and estimate both license costs and internal time spent. Most firms are surprised by what surfaces.
The goal of creating an overview of your capital allocation isn’t to declare a winner among the three strategies. It’s to create alignment between what the firm is actually doing and what leadership says it’s doing.
That alignment matters more than most firms realize. When capital allocation and declared strategy point in different directions, the organization feels it — in decision cycles that slow, in implementation that stalls, and in client conversations where partners give inconsistent answers.
When they point in the same direction, execution stabilizes. Trade-offs don’t disappear, but they become visible and manageable rather than a source of ongoing friction.
In the next blog, we’ll look at the conversation this diagnostic is meant to open — specifically, how to use what your spending reveals to make sequencing explicit — without turning it into a zero-sum negotiation between factions that are all trying to protect something real.